Compare SAIA & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAIA | CYTK |
|---|---|---|
| Founded | 1924 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 8.0B |
| IPO Year | 2002 | 2004 |
| Metric | SAIA | CYTK |
|---|---|---|
| Price | $350.47 | $62.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 16 |
| Target Price | ★ $355.22 | $82.38 |
| AVG Volume (30 Days) | 442.9K | ★ 2.2M |
| Earning Date | 02-10-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 10.58 | N/A |
| Revenue | ★ $3,233,286,000.00 | $87,211,000.00 |
| Revenue This Year | $2.30 | $339.72 |
| Revenue Next Year | $4.81 | $79.08 |
| P/E Ratio | $33.16 | ★ N/A |
| Revenue Growth | 1.96 | ★ 2609.26 |
| 52 Week Low | $229.12 | $29.31 |
| 52 Week High | $538.03 | $70.98 |
| Indicator | SAIA | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 55.88 | 47.75 |
| Support Level | $350.43 | $60.30 |
| Resistance Level | $363.60 | $65.08 |
| Average True Range (ATR) | 12.81 | 2.91 |
| MACD | -0.94 | -0.01 |
| Stochastic Oscillator | 51.40 | 45.74 |
Saia ranks among the 10 largest less-than-truckload carriers in the United States, with more than 200 facilities and a fleet of more than 6,500 tractors and 26,000 trailers. As a national LTL carrier, the firm offers time-definite and expedited options for shipments ranging between 100 and 10,000 pounds. Saia ranks among the top-tier providers in terms of profitability.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.